SG11201810220XA - Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal - Google Patents

Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal

Info

Publication number
SG11201810220XA
SG11201810220XA SG11201810220XA SG11201810220XA SG11201810220XA SG 11201810220X A SG11201810220X A SG 11201810220XA SG 11201810220X A SG11201810220X A SG 11201810220XA SG 11201810220X A SG11201810220X A SG 11201810220XA SG 11201810220X A SG11201810220X A SG 11201810220XA
Authority
SG
Singapore
Prior art keywords
international
nutritional composition
rule
mammal
probiotic
Prior art date
Application number
SG11201810220XA
Inventor
Nora Schneider
Ellen Mitchell
Carine Blanchard
Chiara Nembrini
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of SG11201810220XA publication Critical patent/SG11201810220XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pediatric Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111H1110111111111111111101111101011H011101011111011111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/002240 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 35/744 (2015.01) A23L 33/00 (2016.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 35/745 (2015.01) A61P 25/22 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 35/747 (2015.01) (21) International Application Number: Declarations under Rule 4.17: PCT/EP2017/066161 — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) (22) International Filing Date: — as to the applicant's entitlement to claim the priority of the 29 June 2017 (29.06.2017) earlier application (Rule 4.17(iii)) — of inventorship (Rule 4.17(iv)) (25) Filing Language: English (26) Publication Language: English Published: — with international search report (Art. 21(3)) (30) Priority Data: 16177649.7 01 July 2016 (01.07.2016) EP (71) Applicant: NESTEC S.A. [CH/CH]; Av. Nestle 55, 1800 VEVEY (CH). (72) Inventors: SCHNEIDER, Nora; Rte de la Croix-Blanche 31, 1066 Epalinges Vaud (CH). MITCHELL, Ellen, Siob- _ han; 109 Grandview Ave, White Plains, NY 10605 (US). BLANCHARD, Carine; Chemin de Longeraie 50, 1052 Le — = Mont-sur-Lausanne (CH). NEMBRINI, Chiara; 34, Route de Palezieux, 1610 Oron-La-Ville (CH). = (74) Agent: NAUDE, Dawn; Nestec SA, Centre de Recherche Nestle, Case postale 44 Vers-chez-les-Blanc, 1000 = = LAUSANNE 26 (CH). = (81) Designated States (unless otherwise indicated, for every = kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, — PA, PE, PG, PH, PL, PT, RO, RS, RU, RW, SA, OM, QA, = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = (84) Designated States (unless otherwise indicated, for every = kind ARIPO of regional protection available): (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = — UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European AT, BE, BG, CH, CY, CZ, DE, DK, (AL, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 ..! (54) Title: NUTRITIONAL COMPOSITION COMPRISING A PROBIOTIC FOR THE PREVENTION AND/OR TREATMENT OF ANXIETY DISORDERS AND RELATED CONDITIONS IN A MAMMAL 71' (57) : The invention concerns a composition comprising probiotic selected from the group consisting of Lactococcus lactis and el ei a combination of Bifidobacterium longum and Lactobacillus rhamnosus, preferably strain Lactococcus lactis or a combination of strains 0 ) Lactobacillus rhamnosus LPR and Bifidobacterium longum BL 999, for use in preventing and/or treating anxiety disorders and related 0 --..., conditions like chronic stress, depression and mood regulation in a mammal. The composition is preferably a nutritional composition for 01 : humans, more specifically selected from the group consisting of pregnant women, lactating women and children, even more preferably C by pregnant women, lactating women or infants. In a preferred embodiment, the nutritional composition is an infant formula. ei C
SG11201810220XA 2016-07-01 2017-06-29 Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal SG11201810220XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16177649 2016-07-01
PCT/EP2017/066161 WO2018002240A1 (en) 2016-07-01 2017-06-29 Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal

Publications (1)

Publication Number Publication Date
SG11201810220XA true SG11201810220XA (en) 2018-12-28

Family

ID=56321833

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810220XA SG11201810220XA (en) 2016-07-01 2017-06-29 Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal
SG11201809593YA SG11201809593YA (en) 2016-07-01 2017-06-29 Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201809593YA SG11201809593YA (en) 2016-07-01 2017-06-29 Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal

Country Status (9)

Country Link
EP (2) EP3478306B1 (en)
CN (2) CN109310717A (en)
BR (2) BR112018075625A2 (en)
CA (2) CA3029145A1 (en)
ES (1) ES2969755T3 (en)
MX (2) MX2018014798A (en)
PH (2) PH12018502300A1 (en)
SG (2) SG11201810220XA (en)
WO (2) WO2018002240A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7154473B2 (en) 2017-05-31 2022-10-18 学校法人順天堂 Fatigue Recovery and/or Fatigue Accumulation Prevention Composition
AU2017416677B2 (en) * 2017-06-02 2022-09-29 University Of Otago Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
WO2019141465A1 (en) * 2018-01-18 2019-07-25 Dupont Nutrition Biosciences Aps Probiotics for cognitive and mental health
CN112074193A (en) 2018-01-29 2020-12-11 精密生物集团有限公司 A composition for preventing and treating irritable bowel syndrome
EP3746098A1 (en) 2018-01-29 2020-12-09 PrecisionBiotics Group Limited Bifidobacterium longum
EP3746096A1 (en) 2018-01-29 2020-12-09 PrecisionBiotics Group Limited Bifidobacterium longum ncimb 41676
JP2020039308A (en) * 2018-09-12 2020-03-19 キリンホールディングス株式会社 Composition for improving labor performance
ES2763350B2 (en) * 2018-11-28 2020-10-13 Consejo Superior Investigacion STRAIN OF CHRISTENSENELLA MINUTE AND USE OF THE SAME
JP7406325B2 (en) * 2019-08-08 2023-12-27 森永乳業株式会社 Composition for preventing or improving separation anxiety disorder
IT202000008482A1 (en) * 2020-04-21 2021-10-21 Montefarmaco Otc S P A ORAL COMPOSITION CONTAINING S-ADENOSYL METHIONINE (SAME) AND AT LEAST ONE PROBIOTIC AND ITS USE
CN114098084A (en) * 2021-04-13 2022-03-01 中国人民解放军军事科学院军事医学研究院 Probiotic composition for relieving cognitive impairment caused by long-term low-dose radiation exposure and application thereof
CN113288918B (en) * 2021-06-23 2022-11-08 中南大学 Application of probiotics in preparation of medicine for treating injury of offspring caused by stress during pregnancy
WO2023111270A1 (en) * 2021-12-16 2023-06-22 Biopolis, S. L. Use of postbiotics in the treatment and/or prevention of anxiety disorders
CN116076734B (en) * 2022-10-26 2024-04-26 健码制药(广东)有限公司 Traditional Chinese medicine/probiotic/prebiotic microecological preparation for resisting oxidization and depression and preparation and application thereof
CN116138457A (en) * 2022-12-14 2023-05-23 温州医科大学 Composite nutritional composition with depression symptom relieving effect

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027348A1 (en) * 2007-08-27 2011-02-03 Janos Feher Composition and method inhibiting inflammation
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
CA2742476A1 (en) * 2008-11-03 2010-06-03 Nestec S.A. A nutritional composition comprising probiotics and improving sleep patterns
AU2011351420A1 (en) * 2010-12-29 2013-07-18 Nestec S.A. Fiber and probiotics for reducing intestinal symptoms related to chronic stress
CN103415297A (en) * 2010-12-29 2013-11-27 雀巢产品技术援助有限公司 A nutritional composition comprising fiber and probiotics for reducing stress-related intestinal symptoms
EP2609814A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of cognitive function
EP3079485B2 (en) * 2013-12-13 2022-03-30 Société des Produits Nestlé S.A. Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions
US20150305384A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
US20160058808A1 (en) * 2014-09-03 2016-03-03 California Institute Of Technology Microbe-based modulation of serotonin biosynthesis

Also Published As

Publication number Publication date
CN109310717A (en) 2019-02-05
CA3023166A1 (en) 2018-01-04
PH12018502300A1 (en) 2019-09-23
EP3478306A1 (en) 2019-05-08
WO2018002240A1 (en) 2018-01-04
PH12018502406A1 (en) 2019-09-30
EP3478305A1 (en) 2019-05-08
MX2018014559A (en) 2019-03-28
SG11201809593YA (en) 2018-11-29
EP3478306B1 (en) 2023-11-01
BR112018075625A2 (en) 2019-03-19
CA3029145A1 (en) 2018-01-04
BR112018074867A2 (en) 2019-03-06
WO2018002238A1 (en) 2018-01-04
CN109310716A (en) 2019-02-05
MX2018014798A (en) 2019-04-29
ES2969755T3 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
SG11201810220XA (en) Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal
SG11201810117WA (en) Human platelet lysate derived extracellular vesicles for use in medicine
SG11201811227QA (en) Method for facilitating maturation of the mammalian immune system
SG11201807195VA (en) Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
SG11201807778YA (en) Bicyclic compounds for diagnosis and therapy
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201809470RA (en) Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201807811RA (en) Food compositions for weaning
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201806057QA (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201803338VA (en) Culinary seasoning or bouillon tablet
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201807963WA (en) Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus
SG11201806545WA (en) Compositions comprising fatty acids and their use
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201808540SA (en) Methods of treatment for cholestatic and fibrotic diseases
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201806127XA (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate
SG11202000141WA (en) Powder solid dispersions comprising quercetin, process for their preparation and formulations thereof
SG11201811246RA (en) Novel silybum marianum achene extract and uses thereof in dermatology and dermo-cosmetics
SG11201811311VA (en) Compounds for imaging tau protein aggregates